GALRs, receptors for the neuropeptide galanin, have emerged as potential therapeutic targets for inflammatory bowel disease. Here the authors report that GAL53, a long galanin peptide derived from non-mammalian vertebrates, alleviates induced colitis in preclinical models by engaging GALR2 and activating the β-arrestin2-biased signalling pathway.
- Shanshan Lai
- Xianglin Kong
- Cheng Deng
